Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients

Hemodialysis International

Volumn 14, Issue 1, 2010, Pages 68-72

  Gincherman, Yekaterina ^a   Moloney, Kirsten ^b   Mckee, Charles ^b   Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kilgore's Medical Pharmacy   (United States)

Author keywords

Bone metabolism; Calcimimetic; Medication adherence; Secondary hyperparathyroidism

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CINACALCET; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPHTHALENE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE SYSTEM; HEMODIALYSIS PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; SECONDARY HYPERPARATHYROIDISM; COHORT ANALYSIS; HYPERPARATHYROIDISM, SECONDARY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

COHORT STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PATIENT COMPLIANCE; RENAL DIALYSIS;

EID: 77449137957     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00397.x     Document Type: Article

References (28)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14-S19.
2. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995, 333:166-174.
3. Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism. Nephrol Dial Transplant 2007, 22:637-640.
4. Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2006, CD006254
5. Gal-Moscovici A, Sprague SM. The role of calcimimetics in chronic kidney disease. Kidney Int 2006, 70:S68-S72.
6. Block GA, Martin KJ, de Francisco AL. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004, 350:1516-1525.
7. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006, 260:177-182.
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
9. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2006, 107-120. U.S. Renal Data System. Chapter 5: Clinical Indicators and Preventive Care, In, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
10. Curtin RB, Svarstad BL, Keller TH. Hemodialysis patients' noncompliance with oral medications. Anna J 1999, 26:307-316. discussion 317, 335
11. Denhaerynck K, Manhaeve D, Dobbels F, Garzoni D, Nolte C, De Geest S. Prevalence and consequences of nonadherence to hemodialysis regimens. Am J Crit Care 2007, 16:222-235. quiz 236
12. Kawata T, Imanishi Y, Kobayashi K. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 2006, 24:300-306.
13. Rahman M, Griffin V. Patterns of antihypertensive medication use in hemodialysis patients. Am J Health Syst Pharm 2004, 61:1473-1478.
14. Degli Esposti L, Degli Esposti E, Valpiani G. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002, 24:1347-1357. discussion 1346
15. Degli_Esposti L, Di Martino M, Saragoni S. Pharmacoeconomics of antihypertensive drug treatment: An analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich) 2004, 6:76-84.
16. Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003, 92:1106-1108.
17. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004, 10:122-129.
18. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: Implications for health care costs. Clin Ther 1997, 19:1446-1457. discussion 1424-1445
19. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
20. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence. Am Heart J 2003, 145:438-444.
21. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991, 13:489-495.
22. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004, 27:117-124.
23. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 2001, 57:589-594.
24. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2008, USRDS, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
25. Coburn JW, Maung HM, Elangovan L. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004, 43:877-890.
26. Staniforth ME, Cheng SC, Coyne DW. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin Nephrol 2005, 63:454-460.
27. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003, 63:1483-1490.
28. https://online.epocratis.com/front_porch/, ePocrates_online. Available at, (accessed date: February 11, 2008)